Erika Hamilton, Director of Breast Cancer Program at Sarah Cannon Research Institute, shared a post on LinkedIn:
“Honored to be sharing the latest data on HER2-targeted combination therapy from HER2 CLIMB05 in metastatic breast cancer at ASCO26.
June 2, 11:09 a.m. CDT
Breast Cancer—Metastatic Session
Proud to stand alongside colleagues across Sarah Cannon Research Institute as we continue advancing research that helps bring new options to patients with breast cancer.
Learn more about SCRI’s presence at ASCO.”
Other articles featuring Erika Hamilton on OncoDaily.